ABSTRACT
OBJECTIVE: To provide insights into the potential benefits of goal-directed therapy guided by FloTrac in reducing postoperative complications and improving outcomes. METHODS: We performed a systematic review and meta-analysis of randomized controlled trials to evaluate goal-directed therapy guided by FloTrac in major surgery, comparing goal-directed therapy with usual care or invasive monitoring in cardiac and noncardiac surgery subgroups. The quality of the articles and evidence were evaluated with a risk of bias tool and GRADE. RESULTS: We included 29 randomized controlled trials with 3,468 patients. Goal-directed therapy significantly reduced the duration of hospital stay (mean difference -1.43 days; 95%CI 2.07 to -0.79; I2 81%), intensive care unit stay (mean difference -0.77 days; 95%CI -1.18 to -0.36; I2 93%), and mechanical ventilation (mean difference -2.48 hours, 95%CI -4.10 to -0.86, I2 63%). There was no statistically significant difference in mortality, myocardial infarction, acute kidney injury or hypotension, but goal-directed therapy significantly reduced the risk of heart failure or pulmonary edema (RR 0.46; 95%CI 0.23 - 0.92; I2 0%). CONCLUSION: Goal-directed therapy guided by the FloTrac sensor improved clinical outcomes and shortened the length of stay in the hospital and intensive care unit in patients undergoing major surgery. Further research can validate these results using specific protocols and better understand the potential benefits of FloTrac beyond these outcomes.
Subject(s)
Length of Stay , Postoperative Complications , Humans , Postoperative Complications/epidemiology , Postoperative Complications/prevention & control , Randomized Controlled Trials as Topic , Intensive Care Units , Respiration, Artificial , Early Goal-Directed Therapy/methods , Monitoring, Physiologic/instrumentation , Monitoring, Physiologic/methodsABSTRACT
ABSTRACT Objective To provide insights into the potential benefits of goal-directed therapy guided by FloTrac in reducing postoperative complications and improving outcomes. Methods We performed a systematic review and meta-analysis of randomized controlled trials to evaluate goal-directed therapy guided by FloTrac in major surgery, comparing goal-directed therapy with usual care or invasive monitoring in cardiac and noncardiac surgery subgroups. The quality of the articles and evidence were evaluated with a risk of bias tool and GRADE. Results We included 29 randomized controlled trials with 3,468 patients. Goal-directed therapy significantly reduced the duration of hospital stay (mean difference -1.43 days; 95%CI 2.07 to -0.79; I2 81%), intensive care unit stay (mean difference -0.77 days; 95%CI -1.18 to -0.36; I2 93%), and mechanical ventilation (mean difference -2.48 hours, 95%CI -4.10 to -0.86, I2 63%). There was no statistically significant difference in mortality, myocardial infarction, acute kidney injury or hypotension, but goal-directed therapy significantly reduced the risk of heart failure or pulmonary edema (RR 0.46; 95%CI 0.23 - 0.92; I2 0%). Conclusion Goal-directed therapy guided by the FloTrac sensor improved clinical outcomes and shortened the length of stay in the hospital and intensive care unit in patients undergoing major surgery. Further research can validate these results using specific protocols and better understand the potential benefits of FloTrac beyond these outcomes.
RESUMO Objetivo Fornecer informações sobre os possíveis benefícios da terapia guiada por metas utilizando o sensor FloTrac na redução de complicações pós-operatórias e na melhoria dos desfechos. Métodos Realizamos uma revisão sistemática e uma metanálise de estudos controlados e randomizados para avaliar a terapia guiada por metas utilizando o sensor FloTrac em cirurgias de grande porte, comparando a terapia guiada por metas com os cuidados habituais ou o monitoramento invasivo em subgrupos de cirurgias cardíacas e não cardíacas. A qualidade dos artigos e das evidências foi avaliada com uma ferramenta de risco de viés e o GRADE. Resultados Incluímos 29 estudos controlados e randomizados com 3.468 pacientes. A terapia guiada por metas reduziu significativamente a duração da internação hospitalar (diferença média de -1,43 dia; IC95% 2,07 - -0,79; I2 81%), a internação na unidade de terapia intensiva (diferença média de -0,77 dia; IC95% -1,18 - -0,36; I2 93%) e a ventilação mecânica (diferença média de -2,48 horas, IC95% -4,10 - -0,86; I2 63%). Não houve diferença estatisticamente significativa na mortalidade, no infarto do miocárdio, na lesão renal aguda e nem na hipotensão, mas a terapia guiada por metas reduziu significativamente o risco de insuficiência cardíaca ou edema pulmonar (risco relativo de 0,46; IC95% 0,23 - 0,92; I2 0%). Conclusão A terapia guiada por metas utilizando o sensor FloTrac melhorou os desfechos clínicos e reduziu o tempo de internação no hospital e na unidade de terapia intensiva em pacientes submetidos a cirurgias de grande porte. Outras pesquisas podem validar esses resultados usando protocolos específicos e entender melhor os possíveis benefícios do FloTrac além desses desfechos.